Q32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, provided a fourth-quarter 2025 corporate update that highlights a significantly strengthened balance sheet and clinical progress.
The company announced it has secured a financial runway into the fourth quarter of 2027, bolstered by a mix of asset sales and new capital.
A major driver of this extended liquidity was the divestment of ADX-097, a platform targeting the complement system, to Akebia Therapeutics.
The deal provides Q32 Bio with $12 million in near-term proceeds, of which $7 million has already been received.
Additionally, the company completed a $10.5 million registered direct offering (RDO), further padding its cash position.
As of December 31, 2025, Q32 Bio reported $48.3 million in cash, which—when combined with the RDO and pending sale proceeds—supports operations for the next 18 to 24 months.
On the clinical front, Q32 Bio announced that it has completed enrollment for Part B of its SIGNAL-AA trial.
The study is evaluating bempikibart (ADX-914) in 33 patients with alopecia areata.
This milestone keeps the company on track to release 36-week topline data by mid-2026, a critical catalyst for the bempikibart program, which targets the IL-7 and IL-21 pathways.